Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

Burylo AM, de Weger VA, Stuurman FE, Beijnen JH, Schellens JHM.

Thromb Haemost. 2017 Dec;117(12):2356-2368. doi: 10.1160/TH17-04-0254. Epub 2017 Dec 6.

PMID:
29212123
2.

Changing costs of metastatic non small cell lung cancer in the Netherlands.

Keusters WR, de Weger VA, Hövels A, Schellens JHM, Frederix GWJ.

Lung Cancer. 2017 Dec;114:56-61. doi: 10.1016/j.lungcan.2017.10.005. Epub 2017 Oct 13.

PMID:
29173766
3.

A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.

de Weger VA, Goel S, von Moos R, Schellens JHM, Mach N, Tan E, Anand S, Scott JW, Lassen U.

Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80. doi: 10.1007/s00280-017-3469-4. Epub 2017 Nov 3.

PMID:
29101463
4.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.

Eur J Cancer. 2017 Nov;86:217-225. doi: 10.1016/j.ejca.2017.09.010. Epub 2017 Oct 12.

PMID:
29031170
5.

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.

de Jonge M, de Weger VA, Dickson MA, Langenberg M, Le Cesne A, Wagner AJ, Hsu K, Zheng W, Macé S, Tuffal G, Thomas K, Schellens JH.

Eur J Cancer. 2017 May;76:144-151. doi: 10.1016/j.ejca.2017.02.005. Epub 2017 Mar 17.

PMID:
28324749
6.

Decrease of Patient Costs in the Netherlands: a Cost of Illness Study in Metastatic Non Small Cell Lung Cancer (Nsclc).

Keusters WR, Frederix GW, de Weger VA, Beijnen JH, Hövels AM, Schellens JH.

Value Health. 2015 Nov;18(7):A446. doi: 10.1016/j.jval.2015.09.1113. Epub 2015 Oct 20. No abstract available.

7.

Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.

Turksma AW, Coupé VM, Shamier MC, Lam KL, de Weger VA, Belien JA, van den Eertwegh AJ, Meijer GA, Meijer CJ, Hooijberg E.

Clin Cancer Res. 2016 Jan 15;22(2):346-56. doi: 10.1158/1078-0432.CCR-13-2462. Epub 2015 Sep 29.

8.

Disseminated intravascular coagulation as clinical manifestation of colorectal cancer: a case report and review of the literature.

van Bunderen CC, de Weger VA, Griffioen-Keijzer A.

Neth J Med. 2014 May;72(4):186-9. Review.

9.

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.

de Weger VA, Beijnen JH, Schellens JH.

Anticancer Drugs. 2014 May;25(5):488-94. doi: 10.1097/CAD.0000000000000093. Review. Erratum in: Anticancer Drugs. 2015 Feb;26(2):240.

PMID:
24637579
10.

Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.

de Weger VA, Turksma AW, Voorham QJ, Euler Z, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken JB, van Tinteren H, Meijer GA, Hooijberg E.

Clin Cancer Res. 2012 Feb 1;18(3):882-9. doi: 10.1158/1078-0432.CCR-11-1716. Epub 2011 Dec 12.

Supplemental Content

Loading ...
Support Center